Citation

Le Boisselier R, Alexandre J, Lelong-Boulouard V, Debruyne D. Clin. Pharmacol. Ther. 2016; 101(2): 220-229.

Affiliation

Medical school, Normandy University, F-14032, Caen, France.

Copyright

(Copyright © 2016, American Society for Clinical Pharmacology and Therapeutics, Publisher Nature Publishing Group)

DOI

10.1002/cpt.563

PMID

27861784

Abstract

The recent emergence of a multitude of synthetic cannabinoids (SCs) has generated a wealth of new information, suggesting the usefulness of state-of-the-art on lato sensu cannabinoids. By modulating a plurality of neurotransmission pathways, the endocannabinoid system is involved in many physiological processes increasingly explored. SCs desired and adverse effects are considered to be more intense than those observed with cannabis smoking, which is partly explained by the full agonist activity and higher affinity for cannabinoid receptors. Neurological and cardiovascular side effects observed after cannabinoid poisoning generally respond to conventional supportive care, but severe outcomes may occur in a minority of cases, mainly observed with SCs. The likelihood of severe abuse and addiction produced by SCs are of concern for the scientific community also interested in the potential therapeutic value of cannabinoids. This article is protected by copyright. All rights reserved.

© 2016 American Society for Clinical Pharmacology and Therapeutics.

Language: en